Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M414626200 on January 21, 2005

J. Biol. Chem., Vol. 280, Issue 13, 12461-12466, April 1, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/13/12461    most recent
M414626200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pessi, G.
Right arrow Articles by Mamoun, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pessi, G.
Right arrow Articles by Mamoun, C. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

In Vivo Evidence for the Specificity of Plasmodium falciparum Phosphoethanolamine Methyltransferase and Its Coupling to the Kennedy Pathway*

Gabriella Pessi{ddagger}§, Jae-Yeon Choi¶, Jennifer M. Reynolds{ddagger}§, Dennis R. Voelker¶, and Choukri Ben Mamoun{ddagger}§||

From the {ddagger}Center for Microbial Pathogenesis and §Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, Connecticut 06030 and the Program in Cell Biology, Department of Medicine, National Jewish Medical Research Center, Denver, Colorado 80206

Received for publication, December 28, 2004


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Unlike humans and yeast, Plasmodium falciparum, the agent of the most severe form of human malaria, utilizes host serine as a precursor for the synthesis of phosphatidylcholine via a plant-like pathway involving phosphoethanolamine methylation. The monopartite phosphoethanolamine methyltransferase, Pfpmt, plays an important role in the biosynthetic pathway of this major phospholipid by providing the precursor phosphocholine via a three-step S-adenosyl-L-methionine-dependent methylation of phosphoethanolamine. In vitro studies showed that Pfpmt has strong specificity for phosphoethanolamine. However, the in vivo substrate (phosphoethanolamine or phosphatidylethanolamine) is not yet known. We used yeast as a surrogate system to express Pfpmt and provide genetic and biochemical evidence demonstrating the specificity of Pfpmt for phosphoethanolamine in vivo. Wild-type yeast cells, which inherently lack phosphoethanolamine methylation, acquire this activity as a result of expression of Pfpmt. The Pfpmt restores the ability of a yeast mutant pem1{Delta}pem2{Delta} lacking the phosphatidylethanolamine methyltransferase genes to grow in the absence of choline. Lipid analysis of the Pfpmt-complemented pem1{Delta}pem2{Delta} strain demonstrates the synthesis of phosphatidylcholine but not the intermediates of phosphatidylethanolamine transmethylation. Complementation of the pem1{Delta}pem2{Delta} mutant relies on specific methylation of phosphoethanolamine but not phosphatidylethanolamine. Interestingly, a mutation in the yeast choline-phosphate cytidylyltransferase gene abrogates the complementation by Pfpmt thus demonstrating that Pfpmt activity is directly coupled to the Kennedy pathway for the de novo synthesis of phosphatidylcholine.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
With more than 1 million deaths and 300 million clinical cases annually, malaria is a major worldwide health concern and a major economic burden to the developing world (1). The illness is caused by intraerythrocytic protozoan parasites of the genus Plasmodium. Plasmodium falciparum, which is responsible for the most severe form of the disease, has developed resistance to almost all the available drugs in the antimalarial armamentarium (2). New chemotherapeutic strategies are therefore urgently needed to combat this disease. One strategy is to target the ability of the parasite to synthesize new membranes and inhibit its replication within host erythrocytes. Lipid inhibitors such as choline and phosphocholine analogs have been shown to inhibit P. falciparum membrane biogenesis and to block parasite proliferation (3–7). Some of these compounds are currently being evaluated for treatment of drug-resistant malaria (5).

Biochemical studies have indicated that the synthesis of phosphatidylcholine (PtdCho),1 the major phospholipid in P. falciparum membranes can occur via two metabolic pathways, the de novo choline -> phosphocholine -> CDP-choline pathway, also named the Kennedy pathway, and a newly identified route that we named the serine decarboxylation-phosphoethanolamine methylation (SDPM) pathway (6, 8). The Kennedy pathway initiates with the transport of choline from host serum into the parasite cytoplasm by unidentified erythrocyte and P. falciparum choline transporters. Choline is then converted into PtdCho by the sequential action of choline kinase, choline-phosphate cytidylyltransferase, and CDP-diacyl-glycerol-cholinephosphotransferase (9–12). The SDPM pathway initiates from serine that is either transported from the host or obtained from active degradation of host proteins (13, 14). Serine is first decarboxylated to form ethanolamine by a serine decarboxylase and then phosphorylated to produce phosphoethanolamine (P-Etn) by an ethanolamine kinase (8). P-Etn is subsequently methylated to generate phosphocholine (P-Cho) by a phosphoethanolamine methyltransferase (Pfpmt) (6). The P-Cho enters the Kennedy pathway to form PtdCho. The SDPM pathway has thus far been characterized only in P. falciparum and plants (6, 15–17), and available genomic data suggest that it might also take place in Caenorhabditis elegans, Caenorhabditis briggsae, and Anopheles gambiae (6).

Pfpmt is expressed throughout the intraerythrocytic cycle as well as during the gametocyte and sporozoite stages of the parasite (6, 18, 19). Pfpmt does not share homology with phosphatidylethanolamine (PtdEtn) methyltransferases from lower and higher eukaryotes, and no other homologs of this protein could be found in human or other mammalian data bases (6). Unlike the bipartite structure of plant phosphoethanolamine methyltransferases with two AdoMet-dependent catalytic domains, the malarial Pfpmt is only half the size of plant phosphoethanolamine methyltransferases and possesses a single catalytic domain solely responsible for the three-step AdoMet-dependent methylation of P-Etn into P-Cho (6). Although biochemical studies in vitro showed that Pfpmt and plant phosphoethanolamine methyltransferases were specific for P-Etn and did not catalyze the methylation of PtdEtn (6), one cannot exclude that these phosphoethanolamine methyltransferases (PMT) also catalyze the methylation of PtdEtn in vivo. The difficulty in genetically manipulating P. falciparum, and the fact that yeast cells lack the ability to convert P-Etn into P-Cho make yeast an attractive system to assess the specificity of Pfpmt in vivo. In yeast grown in the absence of choline, the synthesis of PtdCho occurs primarily via the transmethylation of PtdEtn by two methyltransferases encoded by the PEM1 (CHO2) and PEM2 (OPI3) genes (20–22). Individual deletions of PEM1 or PEM2 cause no discernable phenotypes, whereas disruption of both genes is lethal unless choline is provided exogenously and transported via the choline transporter Hnm1 (20, 21). Here we have taken advantage of the extensive biochemical and genetic knowledge of phospholipid metabolism in yeast to examine the in vivo substrate specificity of Pfpmt. Our data provide biochemical and genetic evidence demonstrating that in vivo Pfpmt does not catalyze the transmethylation of PtdEtn to form PtdCho but instead catalyzes the methylation of P-Etn into P-Cho. Furthermore, we show that Pfpmt plays an important role in PtdCho biosynthesis by coupling its activity to the Kennedy pathway.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Strain Construction, Growth Conditions, and Media—The Saccharomyces cerevisiae strains used in this study are described in Table I. Standard methods for yeast culture and manipulation were used (23). Yeast was cultivated at 30 °C in YPD (yeast extract/peptone/dextrose) (24) or in synthetic minimal media containing 2% glucose (SD medium) or 2% galactose (SG medium) supplemented with histidine (30 µg/ml), uracil (30 µg/ml), leucine (100 µg/ml), methionine (100 µg/ml), or choline (140 µg/ml) as required to maintain cell growth.


View this table:
[in this window]
[in a new window]
  		TABLE I
Strains used in this study

 
Plasmid Construction—The codon-optimized PfPMTCO was synthesized using the forward and reverse primers shown in Fig. 2. PfPMTCO was first assembled and amplified as four 200-bp long fragments that were subsequently used as templates to amplify the whole gene. Assembly reactions were performed as described by Santiago et al. (25). The program for assembly is the following: 2 min at 94 °C, 25 cycles of 30 s at 94 °C, 30 s at 55 °C, and 1 min at 68 °C and a 3-min final elongation at 68 °C. The resulting products were purified and used as templates for amplification using the following PCR program: 2 min at 94 °C, 20 cycles of 30 s at 94 °C, 30 s at 63 °C, and 45 s at 68 °C and a 2-min final elongation at 68 °C. The full-length PfPMTCO was TA-cloned into the vector PCR2.1 (Invitrogen). Using the primers 5'-PfPMTCO 5'-ATGACTTTGATCGAGAACTTGAACTCTGATAAGACCTTCCTGGAGAA-3' and 3'-PfPMTCO 5'-GTTCTTGGTGGCCTTGAAGTAAC-3', PfPMTCO was amplified and cloned into the vector pYES2.1-/V5-His-TOPO (Invitrogen), obtaining pYES2.1 GAL1::PfPMTCO. The sequence of PfPMTCO was verified by DNA sequencing.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 2.
Codon optimization of the PfPMT. The nucleotide sequences of PfPMTCO and PfPMT are aligned, and the protein sequence is shown. The oligonucleotides used for assembly and amplification of PfPMTCO are indicated by arrows.

 
Phospholipid Analysis—Wild-type-pYES2.1 and pem1{Delta}pem2{Delta}-PfPMTCO cells were grown overnight in SG medium supplemented with 2 mM ethanolamine and in the absence of choline. The cells were diluted to A600 = 0.005 in 75 ml of fresh SG medium and grown to A600 ~1.5. Cells were harvested and washed twice with water. Lipids were extracted by the Bligh and Dyer method (26) and separated on a two-dimensional thin layer chromatography (TLC). For the first dimension a solvent containing chloroform/methanol/ammonium hydroxide (84.5: 45.5:6:5) was used. The second solvent system was composed of chloroform/glacial acetic acid/methanol/water (90:30:6:2.6). Lipids were stained with iodine vapor. Each lipid spot was excised from the plate and quantified by measuring phosphorus (27). The results are shown as the percentage of total lipid phosphorus in each phospholipid fraction.

Purification of Pfpmt in Yeast and Protein Immunoblotting—S. cerevisiae wild-type and pem1{Delta}pem2{Delta} cells harboring pYES2.1 and pYES2.1 GAL1::PfPMTCO were grown in 50 ml of SD or SG media to A600 = 1 at 30 °C. Extract preparation and purification of the His6-V5-tagged Pfpmt by affinity chromatography were performed as described previously (25). Western blot analysis was performed using affinity-purified proteins from cells grown in minimal medium glucose or galactose. Proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and analyzed by immunoblot using anti-V5 primary (Invitrogen, 1:5000 dilution) and anti-mouse secondary (1:10 000 dilution) antibodies.

Enzyme Assays—Yeast cells were grown in 50 ml of SD or SG media to A600 = 1 at 30 °C and lysed in 50 mM Tris-HCl buffer, pH 8.0, 10% glycerol, 1 mM dithiothreitol, and protease inhibitor mix by agitation with acid-washed glass beads. The 10,000 x g supernatant was dialyzed against 5 mM Hepes, pH 7.8, and 0.5 mM dithiothreitol. Pfpmt was then affinity-purified as recommended by the manufacturer. PMT activity was determined by measuring the incorporation of radioactivity from [methyl-14C]AdoMet into P-Etn as described previously (6). The incubation mixture in a final volume of 100 µl, contained 100 mM Hepes, pH 8.6, 2 mM EDTA, 10% glycerol, 100 µM P-Etn, 100 µM AdoMet (100 nCi of [methyl-14C]AdoMet), and 50 µg of crude extract or affinity-purified recombinant enzyme. The reaction was incubated for 30 min at 30 °C and terminated by the addition of 1 ml of ice-cold H2O. The product was purified through a AG (H+) resin, and the identity of the reaction product was confirmed by TLC using [14C]P-Cho (55 mCi/mmol; ARC) as a standard. Pfpmt activity was also measured using 100 µM ethanolamine and 100 µm PtdEtn as described previously (6). For determination of PtdEtn methyltransferase activity, a PtdEtn emulsion was prepared by sonication in the presence of 0.02% Triton X-100 as described previously (16, 28), and the reaction was performed in Tris buffer, pH 8.5, using 50 µg of crude extract.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Wild-type Yeast Cells Expressing the Codon-optimized PfPMTCO Acquire Phosphoethanolamine Methyltransferase Activity—The inability of the yeast S. cerevisiae to catalyze the three-step methylation of P-Etn for synthesis of P-Cho (Fig. 1) made it possible to assess biochemically and genetically the substrate specificity of P. falciparum Pfpmt in vivo. Because of the high A+T content of PfPMT (72.5% A+T-rich) and to allow its successful expression in yeast, the full codon sequence of the cDNA was reconstructed in vitro to augment its G+C content. Thirty-two 50-nucleotide overlapping primers were first assembled, and the resulting assembly product was used as a template for PCR amplification to create a codon-optimized gene, PfPMTCO, with 51.3% A+T content (Fig. 2). PfPMTCO was then cloned downstream of the GAL1-inducible promoter in the yeast expression vector pYES2.1, which allowed addition of a C-terminal V5-His6 epitope tag to monitor protein expression. As shown in Fig. 3A, expression of Pfpmt could be detected in wild-type yeast cells grown in the presence of galactose, which induces GAL1 promoter-regulated genes but not in the presence of glucose, which represses GAL1 promoter-regulated expression.



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 1.
Phosphatidylcholine metabolism in S. cerevisiae and identification of a complementation strategy to define the substrate specificity of the malarial enzyme Pfpmt. The dotted line shows the PMT activity catalyzed by the P. falciparum Pfpmt. This reaction is absent in S. cerevisiae. Metabolic steps are shown by the arrows, and the known yeast proteins catalyzing each step are indicated in bold.

 



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 3.
Pfpmt expression in S. cerevisiae. A, Western blot analysis was performed using crude extracts from BY4741-pYES2.1 (wild-type, WT) and BY4741-GAL1-PfPMTCO (WT+Pfpmt) grown at 30 °C in minimal medium supplemented with 1 mM choline and containing glucose (Glu) or galactose (Gal) as described under "Materials and Methods." B, S. cerevisiae was grown in SD (Glu) or SG (Gal) media, and the PMT activity was measured in absence (WT) or presence (WT+Pfpmt) of the malarial Pfpmt. PMT activity in S. cerevisiae extracts was determined using phosphoethanolamine (P-Etn) and [14C]AdoMet as substrates. The activity was measured at 30 °C in the presence of 50 µg of S. cerevisiae protein extract, and the product phosphocholine (P-Cho) was purified using AG-50(H+) ion exchange resin. Each value is the mean of duplicate experiments.

 
To determine whether the expression of Pfpmt can provide yeast with the ability to catalyze the three-step methylation of P-Etn into P-Cho, protein extracts were prepared from wild-type cells expressing either GAL1-PfPMTCO or, as a control, the empty vector under galactose and glucose conditions and incubated with the substrate P-Etn and the methyl donor [14C]AdoMet. The products of the reactions were purified by ion exchange chromatography, analyzed by thin layer chromatography, and quantified. Wild-type cells expressing Pfpmt grown in the presence of galactose were able to catalyze the three-step AdoMet-dependent methylation of P-Etn to form P-Cho, whereas the same cells grown in presence of glucose or wild-type cells expressing the empty vector failed to catalyze this reaction (Fig. 3B). Pfpmt was further purified from wild-type cells grown in the presence of galactose by nickel affinity chromatography, and its activity and substrate specificity were analyzed. Similar to the PMT activity measured in P. falciparum extracts or that of the Escherichia coli recombinant-purified enzyme (6), Pfpmt purified from yeast catalyzed the three-step AdoMet-dependent methylation of P-Etn to form P-Cho (Fig. 4, A and B). The enzyme preparation showed only background activity when ethanolamine or PtdEtn were used as substrates (Fig. 4C).



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 4.
Substrate specificity of Pfpmt in S. cerevisiae. A, PMT activity was determined after affinity purification of Pfpmt from an extract of pem1{Delta} pem2{Delta}-GAL1-PfPMTCO cells grown at 30 °C in SD (Glu) or SG (Gal) media. B, TLC analysis of the reaction product P-Cho after purification using AG-50(H+) ion exchange resin. Lane S1, standard [14C]P-Cho. C, substrate specificity of affinity purified Pfpmt, in the presence of 100 µM P-Etn, Etn, and PtdEtn as described under "Materials and Methods." Yeast cells were grown at 30 °C in the presence of glucose or galactose. Each datum represents an average of a duplicate.

 
PfPMTCO Suppresses the Choline Auxotrophy of a Yeast pem1{Delta}pem2{Delta} Mutant—Yeast cells lack PMT activity. However, they express two genes PEM1 and PEM2, which encode two enzymes required for the three-step transmethylation of PtdEtn into PtdCho. Deletion of either PEM1 or PEM2 produces viable strains, whereas deletion of both genes is lethal unless external choline is provided (20, 21). To determine whether expression of Pfpmt can complement the loss of PtdEtn transmethylation, a yeast strain, pem1{Delta}pem2{Delta}, lacking PEM1 and PEM2 was constructed and transformed with the GAL1-PfPMTCO plasmid or the empty vector. The resulting transformants were confirmed to express Pfpmt by immunoblotting using anti-V5 monoclonal antibodies (Fig. 5A) and were further tested for their ability to grow in the absence of choline under inducing (in presence of galactose) and repressing (in presence of glucose) conditions (Fig. 5B). Because of residual choline in agar containing media, the assays were performed in both solid and liquid media. As expected pem1{Delta}pem2{Delta} cells expressing the empty vector required choline for growth under both glucose and galactose conditions. In contrast, pem1{Delta}pem2{Delta} cells expressing GAL1-PfPMTCO were able to grow in the absence of choline when galactose was the sole carbon source but required choline when grown in the presence of glucose (Fig. 5B). These data demonstrate that Pfpmt suppresses the choline auxotrophy of the pem1{Delta}pem2{Delta} mutant.



View larger version (86K):
[in this window]
[in a new window]
  		FIG. 5.
Functional complementation of Pfpmt in S. cerevisiae. A, Western blot analysis was performed using crude extracts from pem1{Delta} pem2{Delta}-pYES2.1 (pem{Delta}) and pem1{Delta} pem2{Delta}-GAL1-PfPMTCO (pem{Delta} Pfpmt) grown at 30 °C in minimal medium supplemented with 1 mM choline and containing glucose or galactose as described under "Materials and Methods." B and C, the strains BY4741-pYES2.1 (wild type, 1), pem1{Delta} pem2{Delta}-pYES2.1 (2), and pem1{Delta} pem2{Delta}-GAL1-PfPMTCO (3) were grown in solid (B) or liquid (C) minimal medium galactose (Gal) or glucose (Glu) with (+Cho) or without (–Cho)1mM choline for 24 h. The growth measurements were performed in both agar medium (left panels) and liquid medium (right panels).

 
PtdCho Biosynthesis by Pfpmt Is Independent of PtdEtn Transmethylation—To confirm that Pfpmt suppression of the choline auxotrophy of pem1{Delta}pem2{Delta} is via restoration of the synthesis of PtdCho, phospholipids were prepared from wild-type and pem1{Delta}pem2{Delta}-GAL1-PfPMTCO cells, grown in absence of choline, analyzed by TLC, and quantified. PtdCho could be detected in both strains (Fig. 6A), although the level of this phospholipid in the pem1{Delta}pem2{Delta}-GAL1-PfPMTCO strain constituted only 32% of what is synthesized by wild-type cells (Fig. 6B). In addition, the PtdEtn level in the pem1{Delta}pem2{Delta}-GAL1-PfPMTCO strain was almost double that of the wild-type cells (Fig. 6), suggesting continuous accumulation of this phospholipid as a result of synthesis via phosphatidylserine decarboxylation and the CDP-ethanolamine pathway. Interestingly, significant amounts of phosphatidyldimethylethanolamine (PtdEtn(Me)2) could be detected in wild-type cells but no intermediates of PtdEtn transmethylation could be detected in the pem1{Delta}pem2{Delta}-GAL1-PfPMTCO cells (Fig. 6). Together these results suggest that Pfpmt-mediated synthesis of PtdCho is not via methylation of PtdEtn but rather via the methylation of P-Etn. To further validate this interpretation we assessed the specificity of protein extracts prepared from wild-type, pem1{Delta}pem2{Delta}, and pem1{Delta}pem2{Delta}-GAL1-PfPMTCO cells for P-Etn versus PtdEtn substrates. Protein extracts from wild-type cells catalyzed the transmethylation of PtdEtn into PtdCho, but showed no specificity toward P-Etn substrate (Fig. 7A). On the other hand, protein extracts from pem1{Delta}pem2{Delta}-GAL1-PfPMTCO cells catalyzed the three-step methylation of P-Etn into P-Cho but showed no specificity for PtdEtn substrate (Fig. 7). As expected protein extracts from pem1{Delta}pem2{Delta} grown in the presence of choline lacked both P-Etn and PtdEtn methylation activities (Fig. 7).



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 6.
Phospholipid analysis. A, wild type (WT) harboring the pYES2.1 vector and complemented (pem1{Delta} pem2{Delta}-GAL1-PfPMTCO) strains were grown in minimal medium plus galactose containing 2 mM ethanolamine until an A600 = 1. Lipids were extracted and separated by a two-dimensional TLC as described under "Materials and Methods." The position of the lipids after iodine staining is shown. B, phospholipid composition. Each lipid was recovered from the TLC plate and quantified by measuring phosphorus. The results are shown as the percentage of total lipid phosphorus in each phospholipid fraction. PtdEtn(Me), dimethyl-PtdEtn; Ptd2Gro, phosphatidylglycerol; PtdOH, phosphatidic acid. Data are means ± S.D. for three independent experiments.

 



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 7.
Methyltransferase activity in S. cerevisiae. A, PtdEtn methyltransferase (MT) activity was determined at 30 °C in 50 µg of protein present in crude extracts from BY4741-pYES2.1 (wild type, 1), pem1{Delta} pem2{Delta}-pYES2.1 (2), and pem1{Delta} pem2{Delta}-GAL1-PfPMTCO (3) using PtdEtn and AdoMet as substrates as described under "Materials and Methods." Each datum represents an average of a duplicate. B, PMT activity in 50 µg of protein present in crude extracts from BY4741-pYES2.1 (wild-type, 1), pem1{Delta} pem2{Delta}-pYES2.1 (2), and pem1{Delta} pem2{Delta}-GAL1-PfPMTCO (3) using P-Etn and AdoMet as substrates. Each datum represents an average of a duplicate.

 
PfPMTCO Complementation of pem1{Delta}pem2{Delta} Mutant Requires a Functional Kennedy Pathway—To evaluate the importance of the CDP-choline pathway in Pfpmt suppression of pem1{Delta}pem2{Delta} choline auxotrophy, we assessed the function of Pfpmt in a pem1{Delta}pct1ts mutant lacking PtdEtn transmethylation activity and altered in the de novo synthesis of PtdCho via the Kennedy pathway (29). This mutant harbors, in addition to a genetic deletion of the PEM1 gene, a spontaneous thermo-sensitive mutation in the PCT1 gene encoding choline-phosphate cytidylyltransferase, the second step in the CDP-choline pathway, thus resulting in a growth defect at 37 °C. Expression of Pfpmt did not complement the thermosensitivity of the pem1{Delta}pct1ts (Fig. 8). As a control the pem1{Delta}pem2{Delta} strain harboring Pfpmt grew normally in the absence of choline at 30 (Fig. 5B) and 37 °C (not shown), whereas the pem1{Delta}pem2{Delta} strain harboring an empty vector required choline for growth at both temperatures (not shown). Together, these results suggest that Pfpmt function is directly coupled to the Kennedy pathway, further demonstrating the specificity of this enzyme for P-Etn in vivo.



View larger version (70K):
[in this window]
[in a new window]
  		FIG. 8.
Pfpmt activity requires a functional Kennedy pathway. CMY134 (pem1{Delta}pct1ts) strain harboring the empty vector pYES2.1 (CMY134-pYES) or pYES2.1 containing PfPMTCO under the control of the GAL1 promoter (CMY134-pYES-PfPMTCO) were grown on SD and SG media lacking (–) or supplemented (+) with choline (Cho) at 30 and 37 °C.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Membrane biogenesis is essential for P. falciparum development and multiplication with human erythrocytes. Understanding this process is an important step toward designing better therapeutic strategies to block parasite replication and eliminate the pathological symptoms associated with the intraerythrocytic cycle of the parasite. Upon infection of human erythrocytes, the phospholipid content of P. falciparum increases by at least 5–6-fold (30). Available data suggest that the synthesis of PtdCho, the major phospholipid in P. falciparum membranes, can occur via two metabolic pathways: the Kennedy pathway that proceeds from choline and a newly identified route that we named the SDPM pathway that proceeds from serine. The Pfpmt enzyme of P. falciparum plays an important role in the SDPM pathway by providing P-Cho via methylation of serine-derived P-Etn (6). The resultant P-Cho then enters the Kennedy pathway for the synthesis of PtdCho. Pfpmt is expressed throughout the intraerythrocytic cycle as well as during the gametocyte and sporozoite stages of the parasite, and possesses a single catalytic domain solely responsible for the three-step AdoMet-dependent methylation of P-Etn to form P-Cho (6).

Because no homologs of PtdEtn methyltransferases could be found in the finished genome sequence of P. falciparum, it remained unclear whether in vivo Pfpmt might also catalyze the three-step methylation of PtdEtn. In the present study we provide genetic and biochemical evidence demonstrating that the primary function of Pfpmt in vivo is to catalyze the methylation of P-Etn to form P-Cho. Six lines of evidence support this important conclusion. First, expression of Pfpmt in wild-type S. cerevisiae cells, which inherently lack P-Etn methyltransferase activity, resulted in their acquiring this activity. Second, PMT activity of wild-type yeast expressing Pfpmt was specific for P-Etn, and no methylation of ethanolamine or PtdEtn could be detected. Third, expression of Pfpmt in a yeast mutant, pem1{Delta}pem2{Delta}, lacking the two genes PEM1 and PEM2, which encode the enzymes Pem1 and Pem2 essential for the synthesis of PtdCho from PtdEtn, resulted in a complete suppression of their requirement for exogenous choline. Fourth, lipid analysis of the pem1{Delta}pem2{Delta} cells expressing Pfpmt demonstrated the synthesis of PtdCho in the absence of choline, but unlike the wild-type strain, no intermediates of the transmethylation of PtdEtn could be detected in the complemented strain. Fifth, the PtdEtn level in the pem1{Delta}pem2{Delta} strain expressing Pfpmt was almost double that of the wild-type cells, suggesting continuous accumulation of this phospholipid as a result of synthesis via phosphatidylserine decarboxylation and the CDP-ethanolamine pathway in conjunction with the elimination of PtdEtn methylation. Finally, complementation of pem1{Delta}pem2{Delta} choline auxotrophy by Pfpmt required a functional Kennedy pathway, because alteration of this pathway by mutation in the PCT1 gene abolishes this complementation.

The ability of Pfpmt to complement pem1{Delta}pem2{Delta} mutant depends on the availability of the P-Etn substrate. In fact, the growth of the complemented strain was much better when the medium was supplemented with ethanolamine (not shown). In the absence of exogenous ethanolamine, this precursor could be obtained either via degradation of sphingosine-1-phosphate by the lyase encoded by the DPL1 gene, or via hydrolysis of PtdEtn by the Ca2+-dependent phospholipase D activity. Interestingly, although the complemented and wild-type strains grew equally well in the absence of choline, the level of PtdCho (as percent total phospholipid) in the complemented strain was only ~4% in the absence (not shown) and ~12% in the presence (Fig. 6) of ethanolamine. In contrast PtdCho was ~40% total phospholipid present in wild-type cells. These data suggest that although PtdCho is the major phospholipid in yeast membranes, its level in wild-type cells far exceeds what is needed for growth and survival, at least under laboratory conditions.

To enhance expression of Pfpmt in yeast, we completely redesigned its cDNA by reducing its A+T content from 72.5 to 51.3% to prevent early transcriptional termination. Successful expression of Pfpmt was demonstrated by inserting a V5-His6 tag in the C-terminal region of the encoded protein and monitoring expression levels using anti-V5 monoclonal antibodies. Pfpmt was further purified from yeast cells by affinity chromatography and used in enzymatic assays. Similar success in complementing yeast after codon optimization was achieved with PfGAT gene of P. falciparum, which encodes a glycerol-3-phosphate acyltransferase of the endoplasmic reticulum important for the initial step of malarial glycerolipid metabolism (25). Pfpmt purified from yeast exhibited the same biochemical properties as the native PMT activity obtained from P. falciparum or recombinant Pfpmt purified from E. coli (6).

Our present results are concordant with previous biochemical analysis using recombinant Pfpmt purified from E. coli and provide strong evidence that Pfpmt exhibits high specificity toward the P-Etn substrate and does not catalyze the methylation of PtdEtn in vivo. Thus it seems that the most critical precursor for the synthesis of PtdCho in P. falciparum is P-Cho, which can be obtained either via Pfpmt methylation of serine-derived P-Etn or by phosphorylation of choline transported by the parasite choline transporter from the host. The relative contribution of the two pathways to the total cellular pool of PtdCho is not yet clear. Recent studies have provided new information about the biochemical properties of the parasite choline transporter (31, 32). However, the genes encoding choline transport activity have not yet been identified in Plasmodium or any other protozoan parasite. More detailed genetic studies in P. falciparum are now needed to evaluate the importance of choline transport and Pfpmt in phospholipid synthesis as it relates to parasite development and survival.

In summary, we have shown that Pfpmt is a highly specific methyltransferase enzyme acting exclusively on P-Etn substrate in vivo. The essential dependence of the pem1{Delta}pem2{Delta} mutant on Pfpmt for growth and survival makes this strain an ideal system to screen for inhibitors that can specifically inhibit Pfpmt activity.


   FOOTNOTES
 
* This work was supported by Grants DAMD17-02-1-0211 and PR033005 from the United States Army Medical Research and Material Command (to C. B. M.) and Grants AI051507 and AI058962 (to C. B. M.) and 2R37-GM32453 and AI030060 (to D. R. V.) from the National Institute of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: Center for Microbial Pathogenesis, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030. Tel.: 860-679-3544; Fax: 860-679-8130; E-mail: choukri{at}up.uchc.edu.

1 The abbreviations used are: PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; Pfpmt, P. falciparum phosphoethanolamine methyltransferase; AdoMet, S-adenosyl-L-methionine; P-Cho, phosphocholine; P-Etn, phosphoethanolamine; PtdIns, phosphatidylinositol; PMT, phosphoethanolamine methyltransferase; SDPM, serine decarboxylation-phosphoethanolamine methylation. Back


   ACKNOWLEDGMENTS
 
We thank Christopher R. McMaster at Dalhousie University, Canada for providing the CMY134 strain.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. WHO Expert Committee of Malaria (2000) World Health Organ. Tech. Rep. Ser. 892, 1–74
  2. White, N. J. (2004) J. Clin. Investig. 113, 1084–1092[CrossRef][Medline] [Order article via Infotrieve]
  3. Ancelin, M. L., Calas, M., Bompart, J., Cordina, G., Martin, D., Ben Bari, M., Jei, T., Druilhe, P., and Vial, H. J. (1998) Blood 91, 1426–1437[Abstract/Free Full Text]
  4. Calas, M., Ancelin, M. L., Cordina, G., Portefaix, P., Piquet, G., Vidal-Sailhan, V., and Vial, H. (2000) J. Med. Chem. 43, 505–516[CrossRef][Medline] [Order article via Infotrieve]
  5. Wengelnik, K., Vidal, V., Ancelin, M. L., Cathiard, A. M., Morgat, J. L., Kocken, C. H., Calas, M., Herrera, S., Thomas, A. W., and Vial, H. J. (2002) Science 295, 1311–1314[Abstract/Free Full Text]
  6. Pessi, G., Kociubinski, G., and Mamoun, C. B. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 6206–6211[Abstract/Free Full Text]
  7. Roggero, R., Zufferey, R., Minca, M., Richier, E., Calas, M., Vial, H., and Ben Mamoun, C. (2004) Antimicrob. Agents Chemother. 48, 2816–2824[Abstract/Free Full Text]
  8. Elabbadi, N., Ancelin, M. L., and Vial, H. J. (1997) Biochem. J. 324, 435–445
  9. Vial, H. J., Thuet, M. J., and Philippot, J. R. (1982) J. Protozool. 29, 258–263[Medline] [Order article via Infotrieve]
  10. Vial, H. J., Thuet, M. J., Broussal, J. L., and Philippot, J. R. (1982) J. Parasitol. 68, 379–391[CrossRef][Medline] [Order article via Infotrieve]
  11. Vial, H., and Ancelin, M. L. (1998) in Malaria: Parasite Biology, Pathogenesis, and Protection (Sherman, I., ed) pp. 159–175, ASM Press, Washington, D. C.
  12. Ancelin, M. L., and Vial, H. J. (1989) Biochim. Biophys. Acta 1001, 82–89[Medline] [Order article via Infotrieve]
  13. Francis, S. E., Sullivan, D. J., Jr., and Goldberg, D. E. (1997) Annu. Rev. Microbiol. 51, 97–123[CrossRef][Medline] [Order article via Infotrieve]
  14. Kirk, K. (2001) Physiol. Rev. 81, 495–537[Abstract/Free Full Text]
  15. Bolognese, C. P., and McGraw, P. (2000) Plant Physiol. 124, 1800–1813[Abstract/Free Full Text]
  16. Nuccio, M. L., Ziemak, M. J., Henry, S. A., Weretilnyk, E. A., and Hanson, A. D. (2000) J. Biol. Chem. 275, 14095–14101[Abstract/Free Full Text]
  17. Charron, J. B., Breton, G., Danyluk, J., Muzac, I., Ibrahim, R. K., and Sarhan, F. (2002) Plant Physiol. 129, 363–373[Abstract/Free Full Text]
  18. Bahl, A., Brunk, B., Coppel, R. L., Crabtree, J., Diskin, S. J., Fraunholz, M. J., Grant, G. R., Gupta, D., Huestis, R. L., Kissinger, J. C., Labo, P., Li, L., McWeeney, S. K., Milgram, A. J., Roos, D. S., Schug, J., and Stoeckert, C. J., Jr. (2002) Nucleic Acids Res. 30, 87–90[Abstract/Free Full Text]
  19. Le Roch, K. G., Zhou, Y., Blair, P. L., Grainger, M., Moch, J. K., Haynes, J. D., De La Vega, P., Holder, A. A., Batalov, S., Carucci, D. J., and Winzeler, E. A. (2003) Science 301, 1503–1508[Abstract/Free Full Text]
  20. Kodaki, T., and Yamashita, S. (1987) J. Biol. Chem. 262, 15428–15435[Abstract/Free Full Text]
  21. Summers, E. F., Letts, V. A., McGraw, P., and Henry, S. A. (1988) Genetics 120, 909–922[Abstract/Free Full Text]
  22. Carman, G. M., and Henry, S. A. (1989) Annu. Rev. Biochem. 58, 635–669[CrossRef][Medline] [Order article via Infotrieve]
  23. Guthrie, C., and Fink, G. R. (1991) Guide to Yeast Genetics and Molecular Biology in Methods in Enzymology, Academic Press, San Diego
  24. Kanipes, M. I., Hill, J. E., and Henry, S. A. (1998) Genetics 150, 553–562[Abstract/Free Full Text]
  25. Santiago, T. C., Zufferey, R., Mehra, R. S., Coleman, R. A., and Mamoun, C. B. (2004) J. Biol. Chem. 279, 9222–9232[Abstract/Free Full Text]
  26. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Med. Sci. 37, 911–917
  27. Rouser, G., Siakatose, A. N., and Fleischer, S. (1996) Lipids 1, 85–86
  28. Ridgway, N. D., and Vance, D. E. (1992) Methods Enzymol. 209, 366–374[Medline] [Order article via Infotrieve]
  29. Howe, A. G., Zaremberg, V., and McMaster, C. R. (2002) J. Biol. Chem. 277, 44100–44107[Abstract/Free Full Text]
  30. Sherman, I. W. (1979) Microbiol. Rev. 43, 453–495[Free Full Text]
  31. Lehane, A. M., Saliba, K. J., Allen, R. J., and Kirk, K. (2004) Biochem. Biophys. Res. Commun. 320, 311–317[CrossRef][Medline] [Order article via Infotrieve]
  32. Biagini, G. A., Pasini, E. M., Hughes, R., De Koning, H. P., Vial, H. J., O`Neill P, M., Ward, S. A., and Bray, P. G. (2004) Blood 104, 3372–3377[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
W. H. Witola, K. El Bissati, G. Pessi, C. Xie, P. D. Roepe, and C. B. Mamoun
Disruption of the Plasmodium falciparum PfPMT Gene Results in a Complete Loss of Phosphatidylcholine Biosynthesis via the Serine-Decarboxylase-Phosphoethanolamine-Methyltransferase Pathway and Severe Growth and Survival Defects
J. Biol. Chem., October 10, 2008; 283(41): 27636 - 27643.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Signorell, M. Rauch, J. Jelk, M. A. J. Ferguson, and P. Butikofer
Phosphatidylethanolamine in Trypanosoma brucei Is Organized in Two Separate Pools and Is Synthesized Exclusively by the Kennedy Pathway
J. Biol. Chem., August 29, 2008; 283(35): 23636 - 23644.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Reynolds, S. Takebe, J.-Y. Choi, K. El Bissati, W. H. Witola, A. M. Bobenchik, J. C. Hoch, D. R. Voelker, and C. B. Mamoun
Biochemical and Genetic Analysis of the Phosphoethanolamine Methyltransferase of the Human Malaria Parasite Plasmodium falciparum
J. Biol. Chem., March 21, 2008; 283(12): 7894 - 7900.
[Abstract] [Full Text] [PDF]

Home page
 Eukaryot CellHome page
W. H. Witola and C. Ben Mamoun
Choline Induces Transcriptional Repression and Proteasomal Degradation of the Malarial Phosphoethanolamine Methyltransferase
Eukaryot. Cell, September 1, 2007; 6(9): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Eukaryot CellHome page
S. Takebe, W. H. Witola, B. Schimanski, A. Gunzl, and C. Ben Mamoun
Purification of Components of the Translation Elongation Factor Complex of Plasmodium falciparum by Tandem Affinity Purification
Eukaryot. Cell, April 1, 2007; 6(4): 584 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Choubey, P. Maity, M. Guha, S. Kumar, K. Srivastava, S. K. Puri, and U. Bandyopadhyay
Inhibition of Plasmodium falciparum Choline Kinase by Hexadecyltrimethylammonium Bromide: a Possible Antimalarial Mechanism
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 696 - 706.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. H. Witola, G. Pessi, K. El Bissati, J. M. Reynolds, and C. B. Mamoun
Localization of the Phosphoethanolamine Methyltransferase of the Human Malaria Parasite Plasmodium falciparum to the Golgi Apparatus
J. Biol. Chem., July 28, 2006; 281(30): 21305 - 21311.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/13/12461    most recent
M414626200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pessi, G.
Right arrow Articles by Mamoun, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pessi, G.
Right arrow Articles by Mamoun, C. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement